|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 9/64 | (2006.01) |
| A61K 38/4846 | (2013.01) | ||
| C12N 15/55 | (2006.01) | ||
| A61P 7/04 | (2018.01) | ||
| A61K 38/43 | (2006.01) | ||
| C12N 9/644 | (2013.01) | ||
| C12Y 304/21022 | (2013.01) |
| (11) | Number of the document | 3663399 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19218636.9 |
| Date of filing the European patent application | 2011-11-03 | |
| (97) | Date of publication of the European application | 2020-06-10 |
| (45) | Date of publication and mention of the grant of the patent | 2021-12-22 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 45629810 P | 2010-11-03 | US |
| (72) |
MADISON, Edwin L , US
THANOS, Christopher , US
BLOUSE, Grant Ellsworth , US
|
| (73) |
Catalyst Biosciences, Inc. ,
611 Gateway Blvd., Suite 710, South San Francisco, CA 94080,
US
|
| (54) | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF |
| MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF |